Prostate cancer drugs put to the test: which one protects your mind?
NCT ID NCT04335682
Summary
This study aims to find out which of two common prostate cancer medications—enzalutamide or darolutamide—has less impact on memory, concentration, and other thinking skills. About 111 men with advanced prostate cancer will take one of the drugs and complete regular computer-based tests to measure changes in their cognitive function over 48 weeks. The goal is to help doctors choose treatments that better preserve patients' quality of life and mental sharpness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
University of California - San Francisco at Mount Zion
San Francisco, California, 94115, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Kansas Cancer Center
Fairway, Kansas, 66205, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
University of Oklahoma
Oklahoma City, Oklahoma, 73104, United States
Conditions
Explore the condition pages connected to this study.